Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.
van der Wel JWT, Jebbink M, van den Broek D, Steinbusch LC, Theelen WSME, Ruiter G, Buikhuisen W, Burgers JA, Baas P, Vermeulen M, van der Noort V, Hashemi SMS, Bosch LJW, Monkhorst K, Smit EF, Boelens MC, de Langen AJ.
van der Wel JWT, et al. Among authors: hashemi sms.
Lung Cancer. 2024 Sep 28;198:107972. doi: 10.1016/j.lungcan.2024.107972. Online ahead of print.
Lung Cancer. 2024.
PMID: 39556978